Exercise Trends Reported in Parkinson’s Patients
Objective: To examine trends in type, frequency, and effectiveness of exercise in Parkinson’s patients based on gender, race, and years since diagnosis. Background: Exercise has…Co-speech gestures in Parkinson’s disease (PD)
Objective: We develop an analytical description of co-speech gesture production in PD patients. Background: Communication and expressive behavior problems are frequent in PD patients (Duncan…Interaction of dietary protein with levodopa in Parkinson disease.
Objective: To study the effect of dietary protein on levodopa effectiveness in Parkinson disease (PD) patients. Background: Levodopa transport across the blood brain barrier is…Fibroblasts Implanted in Internal Pallidum of Parkinsonian Macaques Exert L-Dopa-Sparing Activity
Objective: To assess the effects of autologous implantation of fibroblasts in the internal globus pallidus of dyskinetic MPTP-lesioned monkeys upon motor behaviour and L-DOPA response.…Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity
Objective: To investigate the mechanism(s) of action of xenon inhalation for the treatment of L-DOPA-induced dyskinesia. Background: L-dopa-induced dyskinesia (LID) is one of the most…Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease
Objective: To develop a communication calendar (CC) to facilitate information exchange about outpatients treated by various therapists in order to optimize interdisciplinary therapy of Parkinson's…Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial
Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity
Objective: To study whether incobotulinumtoxinA (INCO), a new, low-antigenicity botulinum toxin (BT) drug, increases BT antibody (BTAB) titers in patients with antibody-induced therapy failure (ABTF)…Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…Focused ultrasound subthalatomy restores intracortical inhibition in PD
Objective: To test the effects of focused ultrasound subthalatomy on motor cortex excitability in Parkinson’s disease (PD). Background: Short-interval intracortical inhibition (SICI), a GABAAR-mediated inhibition…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.